Impact of concurrent antibody–drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study

• DOI: 10.1007/s11060-024-04681-8
• Publication Date: 2024-04-22T01:01:35Z
• Authors: Yutaro Koide; Naoya Nagai; Sou Adachi; Masayuki Ito; Mariko Kawamura; Makoto Ito; Fumitaka Ito; Yurika Shindo; Takahiro Aoyama; Hidetoshi Shimizu; Shingo Hashimoto; Hiroyuki Tachibana; Takeshi Kodaira
• Keywords: Adult; Necrosis; Immunoconjugates; Brain Neoplasms; Humans; Breast Neoplasms; Female; Chemoradiotherapy; Middle Aged; Radiation Injuries; Retrospective Studies; Aged; Follow-Up Studies

We aimed to investigate the impact of concurrent antibody-drug conjugates (ADC) and radiotherapy on symptomatic radiation necrosis (SRN) in breast cancer patients with brain metastases (BM).This multicenter retrospective study uses four institutional data. Eligibility criteria were histologically proven breast cancer, diagnosed BM with gadolinium-enhanced MRI, a Karnofsky performance status of 60 or higher, and radiotherapy for all BM lesions between 2017 and 2022. Patients with leptomeningeal dissemination were excluded. Concurrent ADC was defined as using ADC within four weeks before or after radiotherapy. The cumulative incidence of SRN until December 2023 with death as a competing event was compared between the groups with and without concurrent ADC. Multivariable analysis was performed using the Fine-Gray model.Among the 168 patients enrolled, 48 (29%) received ADC, and 19 (11%) had concurrent ADC. Of all, 36% were HER2-positive, 62% had symptomatic BM, and 33% had previous BM radiation histories. In a median follow-up of 31 months, 18 SRNs (11%) were registered (11 in grade 2 and 7 in grade 3). The groups with and without concurrent ADC had 5 SRNs in 19 patients and 13 SRNs in 149, and the two-year cumulative incidence of SRN was 27% vs. 7% (P = 0.014). Concurrent ADC was associated with a higher risk of SRN on multivariable analysis (subdistribution hazard ratio, 3.0 [95% confidence interval: 1.1-8.3], P = 0.030).This study suggests that concurrent ADC and radiotherapy are associated with a higher risk of SRN in HER2-positive breast cancer patients.